BLI Stock Price, News & Analysis

Berkeley Lights (Nasdaq: BLI) announced a leadership transition as CEO Eric D. Hobbs moves to president of Antibody Therapeutics. In 2021, the company achieved a revenue increase of over 30%, with projected revenue for 2022 expected to grow by 30% as well. Revenue from partnerships and services surged three-fold in 2021, contributing 20% of total revenue. Berkeley Lights plans to leverage its technology to enhance biotherapeutics development. The board is engaging an executive search firm to find a new CEO while maintaining operational continuity.

Berkeley Lights (Nasdaq: BLI) will participate virtually in the 40th Annual J.P. Morgan Healthcare Conference, scheduled for January 11, 2022, at 12:45 p.m. Pacific Time. A live and archived webcast will be available on their Investors section of the website.

Berkeley Lights is at the forefront of digital cell biology, offering a platform that enhances the development of biotherapeutics through advanced automation and software. Their proprietary technology enables comprehensive analysis of single cells, supporting efficient commercialization of cell-based products.

Berkeley Lights Appoints New Independent Director

Berkeley Lights (Nasdaq: BLI) announces the appointment of Jessica Hopfield, Ph.D., as an independent director, effective December 15, 2021. With over 20 years of experience in medical devices and biotechnology, Dr. Hopfield's strategic insight aims to enhance the company's performance in cell biology applications. Dr. Hopfield, a seasoned consultant, previously worked at McKinsey & Company and holds qualifications from Yale, Harvard, and Rockefeller University. Her addition to the Board is expected to drive growth and value for shareholders.

Berkeley Lights, Inc. (BLI) announced its participation at the Antibody Engineering & Therapeutics meeting, showcasing the Beacon Optofluidic System for antibody discovery. The new single B-cell service offerings enhance recovery of thousands of hits by screening 100,000 plasma B cells. Genovac will present on strategies for antibody discovery against difficult targets, leveraging genetic immunization technology. The developments aim to accelerate commercial success and address challenges in therapeutic antibody development.

Berkeley Lights, Inc. (BLI) has announced its acquisition of the Beacon® system by MImAbs SAS, enhancing antibody discovery for cancer and inflammatory diseases. This represents the first Beacon platform in France, replacing MImAbs’ hybridoma system. The Beacon system enables screening of up to 100,000 B cells and reduces processing time from 60 days to 7 days. MImAbs CEO Thierry Jean highlighted its ability to deliver superior results and competitive advantages in antibody development. Berkeley Lights aims to accelerate the drug development process and improve patient outcomes.

Berkeley Lights, Inc. (Nasdaq: BLI) announced its participation in the Stifel 2021 Virtual Healthcare Conference, scheduled for November 16 at 1:00 p.m. PT / 4:00 p.m. ET. The company will engage in a fireside chat, which can be accessed through a live and archived webcast on their website. Berkeley Lights is known for its innovative digital cell biology solutions that accelerate biotherapeutic development. Their platform provides critical data on single cells, enhancing research capabilities in cell-based products.

Berkeley Lights (Nasdaq: BLI) reported a record third quarter 2021 revenue of $24.3 million, achieving a growth of 34% year-over-year. The company placed 13 new systems, raising its total installed base to 105 platforms. Significant purchases included a third Beacon Optofluidic system by Genovac and GlaxoSmithKline, boosting its capacity for antibody therapeutics. However, operational losses widened to $19.98 million as operating expenses surged. The 2021 outlook anticipates revenue in the low $90 million range.

Berkeley Lights, Inc. (Nasdaq: BLI) announced its participation at the 13th Annual PEGS Europe from November 2-4, 2021, in Barcelona. At this summit, Berkeley Lights will present innovative strategies for antibody discovery using the Beacon® Optofluidic System. Key presentations include:

• Bringing Product Quality Assessment into Early Clone Selection on November 2, highlighting its Opto™ CLD workflow.
• Leave No Hit Behind on November 3, showcasing the OPBD 4.0 workflow for lead molecule discovery.

Additionally, CEO Tracey Mullen from Abveris will present lessons learned from two years of data using the Beacon system on November 4.

Berkeley Lights announced that GlaxoSmithKline has acquired an additional Beacon Optofluidic system to enhance its antibody therapeutics capabilities. This strategic move aims to accelerate the functional analysis and lead selection processes in therapeutic development. The purchase is part of GSK's commitment to utilizing high-throughput screening technologies, further highlighting the value of Berkeley Lights' platform. The acquisition contributes to GSK's ongoing efforts in biotherapeutics and marks a successful quarter with 13 new platform placements reported.